Kura Oncology Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 83
Employees
  • Stock Symbol
  • KURA
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $29.73
  • (As of Wednesday Closing)

Kura Oncology General Information

Description

Kura Oncology Inc is a clinical-stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 12730 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kura Oncology Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.73 $32.80 $6.35 - $43.00 $1.96B 66M 867K -$1.63

Kura Oncology Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 1,400,909 380,451 352,882 368,535
Revenue 0 0 0 0
EBITDA (84,391) (67,234) (62,636) (35,267)
Net Income (81,331) (63,140) (60,447) (35,434)
Total Assets 339,567 241,972 182,379 95,851
Total Debt 15,426 7,500 7,500 7,098
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kura Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.

Request a free trial

Kura Oncology Executive Team (15)

Name Title Board Seat Contact Info
Troy Wilson Ph.D Chief Executive Officer & Chairman
Marc Grasso MD Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Kathleen Ford Chief Operating Officer, Operations
James Basta Secretary, Administration & Chief Legal Officer, Legal
Kirsten Flowers Executive
You’re viewing 5 of 15 executive team members. Get the full list »

Kura Oncology Board Members (7)

Name Representing Role Since
Diane Parks Self Board Member 000 0000
Faheem Hasnain Self Board Member 000 0000
Mary Szela Self Board Member 000 0000
Robert Hoffman Self Board Member 000 0000
Steven Stein MD Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Kura Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kura Oncology Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000000 06-Mar-2015 000000000000000000 Holding Companies
To view Kura Oncology’s complete acquisitions history, request access »